The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials-Reference-Cited by-同舟云学术

The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials

Published:2014-11-12 Issue:3 Volume:36 Page:1933-1941
ISSN:1010-4283
Container-title:Tumor Biology
language:en
Short-container-title:Tumor Biol.

Author:

Fang Yuan,Qu Xinlan,Cheng Boran,Chen Yuanyuan,Wang Zhenmeng,Chen Fangfang,Xiong Bin

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13277-014-2799-7.pdf

Reference29 articles.

1. Jemal A et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

2. DeSantis C et al. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62.

3. Mariani G. New developments in the treatment of metastatic breast cancer: from chemotherapy to biological therapy. Ann Oncol. 2005;16 Suppl 2:ii191–4.

4. Banerjee S et al. Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol. 2007;4(9):536–50.

5. Marty M, Pivot X. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. Eur J Cancer. 2008;44(7):912–20.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting tumor microenvironment for breast cancer treatment;Role of Tumor Microenvironment in Breast Cancer and Targeted Therapies;2022

2. Breast cancer fibroblasts and cross-talk;Clinica Chimica Acta;2021-10

3. First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study;The Breast;2020-12

4. Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews;JNCI Cancer Spectrum;2020-08-24

5. Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer;Breast Cancer Research and Treatment;2020-04-03